|
| New Model May Simplify High-Dose Radiosurgery Planning | Mon, 06 Sep 2010 |
| There is yet no straightforward way to determine the optimal dose level and treatment schedules for high-dose radiation therapies such as stereotactic radiation therapy, which is used to treat brain and lung cancer, or for high-dose brachytherapy for prostate and other cancers. Radiation oncologists at the Ohio State University Comprehensive Cancer Center-Arthur G... | |
| Light The White House Blue For Prostate Cancer Awareness Month | Sat, 04 Sep 2010 |
| Members of the Prostate Cancer Roundtable, consisting of America's Leading Prostate Cancer Organizations, are asking President Obama to place a blue ribbon on the White House and light the White House blue in the evenings in recognition of Prostate Cancer Awareness Month in September. This visible show of support for prostate cancer awareness by the White House will be a major tribute to the 2... | |
| CyberKnife Treatment For Prostate Cancer | Sat, 04 Sep 2010 |
| CyberKnife radiosurgery treatment for prostate cancer is rapid, effective and has no side effects, with the added benefit of being non-invasive. Since 2003, the CyberKnife Center of Miami and the CyberKnife Center of Palm Beach have been providing this high tech cancer treatment longer than any facility in South Florida... | |
| InSightec Treats First Prostate Cancer Patients In Clinical Trials | Wed, 01 Sep 2010 |
| nSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients. Seven patients with localized low-risk prostate cancer were treated worldwide so far... | |
| Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients In Clinical Trials | Wed, 01 Sep 2010 |
| Elbit Imaging Ltd. (NASDAQ: EMITF) ("Elbit" "Company") that it's subsidiary, InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced that its ExAblate(R) system has been used for the first time for the treatment of prostate cancer patients... | |
| Atrazine Causes Prostate Inflammation In Male Rats And Delays Puberty | Fri, 27 Aug 2010 |
| A new study shows that male rats prenatally exposed to low doses of atrazine, a widely used herbicide, are more likely to develop prostate inflammation and to go through puberty later than non-exposed animals. The research adds to a growing body of literature on atrazine, an herbicide predominantly used to control weeds and grasses in crops such as corn and sugar cane... | |
|
|
| Cost Of Prostate Cancer Care Caries With Initial Treatment Choice | Tue, 24 Aug 2010 |
| A new analysis has found that short-term and long-term costs of prostate cancer care vary considerably based on which treatment strategy a man initially receives. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study finds that treatments that may be less expensive in the short-term may have higher long-term costs... | |
| Cost Of Prostate Cancer Care Varies With Initial Treatment Choice | Tue, 24 Aug 2010 |
| A new analysis has found that short-term and long-term costs of prostate cancer care vary considerably based on which treatment strategy a man initially receives. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study finds that treatments that may be less expensive in the short-term may have higher long-term costs... | |
| Brothers Of Prostate Cancer Patients Undergo More Diagnostic Activities | Sat, 21 Aug 2010 |
| The brothers of men with prostate cancer are at an increased risk of prostate cancer diagnosis because of increased diagnostic activity and not necessarily because they carry a genetic mutation that increases risk of the disease, according to a study published online August 19 in The Journal of the National Cancer Institute... | |
|
|
| Loyola To Offer Free Exams As Part Of National Prostate Awareness Month In September | Wed, 18 Aug 2010 |
| More than 55 million American men are at risk for developing prostate cancer, according to the American Cancer Society. This year more than 27,000 men are expected to die of the disease, which is the second-leading cause of cancer death in men. "Fortunately, caught early enough prostate cancer is highly treatable," said urologist Dr. Robert C... | |
| CRT And ValiRx Sign Licensing Deal To Develop Prostate Cancer Treatment | Mon, 16 Aug 2010 |
| Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer. The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments... | |
|
|
|
| Induction Of Clusterin By AKT--Role In Cytoprotection Against Docetaxel In Prostate Tumor Cells | Wed, 11 Aug 2010 |
| In the online edition of Molecular Cancer Therapeutics, Dr. Bin Zhong and associates report a link between the signal transduction protein AKT and the androgen receptor chaperone protein clusterin (CLU). Two forms of CLU exist; one is secreted (sCLU) and the other localizes in the nucleus (nCLU). sCLU is associated with chemoresistance and overexpression of sCLU induces androgen resistance... | |
| Inhibiting Prostate Cancer Without Disturbing Regular Body Processes | Wed, 11 Aug 2010 |
| A kinase is a type of enzyme the body uses to regulate the functions of the proteins required for cell growth and maintenance, and researchers have discovered that one in particular plays a key role in developing prostate cancer. "It's known as Mnk, and although it appears not to be essential for normal cell maintenance, it's important for cancer growth" said Dr... | |
| CYP17 Polymorphisms And Prostate Cancer Outcomes | Wed, 11 Aug 2010 |
| CYP17 is an enzyme involved in androgen biosynthesis and recently has drawn attention as a target in castration-resistant prostate cancer (CRPC) where it is involved in intracrine androgen biosynthesis, despite androgen deprivation therapy. Abiraterone is a drug that targets CYP17A1 and is in phase III trials for CRPC... | |
|
|
|
|